Filing Flows › Lineage Cell Therapeutics (LCTX) › R&D spending
Lineage Cell Therapeutics (LCTX) R&D spending by quarter
Lineage Cell Therapeutics' R&D spending was $4.8M in Q2 2026 (second quarter 2026), +13% from Q1 2026. Over the last 7 quarters it ranged from $3.1M (Q2 2025) to $8.2M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.8M | +13% | +54% |
| Q1 2026 | $4.2M | -49% | +36% |
| Q4 2025 | $8.2M | +152% | +141% |
| Q3 2025 | $3.3M | +5% | — |
| Q2 2025 | $3.1M | -0.3% | — |
| Q1 2025 | $3.1M | -9% | — |
| Q4 2024 | $3.4M | — | — |
Q2 2026 at a glance
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Lineage Cell Therapeutics' R&D spending?
Lineage Cell Therapeutics' R&D spending was $4.8M in Q2 2026 (second quarter 2026), +13% from Q1 2026.
How has Lineage Cell Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $3.1M (Q2 2025) to $8.2M (Q4 2025).
Q2 2026 results → · How Lineage Cell Therapeutics makes money →